OBJECTIVES
Lupus nephritis (LN) often progresses despite therapy, and current complete renal response (CRR) definitions tolerate residual proteinuria deemed suboptimal in other glomerulopathies. Belimumab, the first biologic approved for active LN, may enable deeper remission, but its real-world effectiveness is unknow...
Marc Xipell, M. C. Garbarino, I. Rodríguez-Pintó et al.· Rheumatology· 0 citations
A perspective of the Immunonephrology Working Group (IWG) of the European Renal Association (ERA) is provided and discusses the key unmet needs in the management of lupus nephritis.
Ş. Özcan, A. Bruchfeld, F. Caravaca-Fontán et al.· Nephrology, Dialysis and Tra...· 0 citations
Ten practical tips to improve clinical decision-making in the diagnosis and management of Nephrotic syndrome are presented to help increase awareness of common pitfalls and support more attentive clinical management of patients with NS.
Ilay Berke, A. Bruchfeld, Eleni Frangou et al.· Clinical Kidney Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.